PharmaShots | Incisive News in 3 Shots

Subscribe Now

BMS

BMS Reports EMA's Validation of Type II Variation Application for Breyanzi (lisocabtagene maraleucel) to Treat R/R Large B-cell Lymphoma

BMS Reports EMA's Validation of Type II Variation Application for Breyanzi (lisocabtagene maraleucel) to Treat R/R Large B-cell Ly...

June 20, 2022

BMS Reports Three and Five-Year Data of Opdivo (nivolumab) + Yervoy (ipilimumab) in P-III (CheckMate -9LA) and (CheckMate -227) Trial for mNSCLC

BMS Reports Three and Five-Year Data of Opdivo (nivolumab) + Yervoy (ipilimumab) in P-III (CheckMate -9LA) and (CheckMate -227) Tr...

June 7, 2022

PharmaShots Weekly Snapshots (May 30 – June 03, 2022)

PharmaShots Weekly Snapshots (May 30 – June 03, 2022)

June 3, 2022

BMS to Acquire Turning Point for ~$4.1B

BMS to Acquire Turning Point for ~$4.1B

June 3, 2022

BMS Presents Results of Deucravacitinib in P-II (PAISLEY) Study for the Treatment of Systemic Lupus Erythematosus at EULAR 2022

BMS Presents Results of Deucravacitinib in P-II (PAISLEY) Study for the Treatment of Systemic Lupus Erythematosus at EULAR 2022

June 2, 2022

BMS’ Opdivo (nivolumab) + Yervoy (ipilimumab) Receives the US FDA Approval as 1L Treatment for Unresectable Advanced or Metastatic Esophageal Squamous Cell Carcinoma

BMS’ Opdivo (nivolumab) + Yervoy (ipilimumab) Receives the US FDA Approval as 1L Treatment for Unresectable Advanced or Metastatic...

May 30, 2022

Contact Us

First Floor, B 150, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us